81 related articles for article (PubMed ID: 3180347)
1. Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Kirchheimer JC; Wojta J; Christ G; Hienert G; Binder BR
Carcinogenesis; 1988 Nov; 9(11):2121-3. PubMed ID: 3180347
[TBL] [Abstract][Full Text] [Related]
2. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
3. Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Kirchheimer JC; Wojta J; Hienert G; Christ G; Heger ME; Pflüger H; Binder BR
Thromb Res; 1987 Nov; 48(3):291-8. PubMed ID: 2448891
[TBL] [Abstract][Full Text] [Related]
4. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
5. Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Marutsuka K; Hasui Y; Asada Y; Naito S; Osada Y; Sumiyoshi A
Clin Exp Metastasis; 1995 Mar; 13(2):116-22. PubMed ID: 7882614
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Hofmann R; Lehmer A; Hartung R; Robrecht C; Buresch M; Grothe F
J Urol; 1996 Mar; 155(3):858-62. PubMed ID: 8583593
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
De Petro G; Copeta A; Barlati S
Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
[TBL] [Abstract][Full Text] [Related]
8. Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Kirchheimer JC; Pflüger H; Hienert G; Binder BR
Int J Cancer; 1985 Jun; 35(6):737-41. PubMed ID: 3924843
[TBL] [Abstract][Full Text] [Related]
9. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Wakita T; Hayashi T; Nishioka J; Tamaru H; Akita N; Asanuma K; Kamada H; Gabazza EC; Ido M; Kawamura J; Suzuki K
Int J Cancer; 2004 Feb; 108(4):516-23. PubMed ID: 14696115
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
11. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
12. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
13. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Wagner SN; Atkinson MJ; Thanner S; Wagner C; Schmitt M; Wilhelm O; Rotter M; Höfler H
Am J Pathol; 1995 Jul; 147(1):183-92. PubMed ID: 7604879
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
15. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
16. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Rømer J; Pyke C; Lund LR; Ralfkiaer E; Danø K
J Invest Dermatol; 2001 Mar; 116(3):353-8. PubMed ID: 11231307
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Bashar H; Urano T; Fukuta K; Pietraszek MH; Hata M; Suzuki K; Kawabe K; Takada Y; Takada A
Urol Int; 1994; 52(1):4-8. PubMed ID: 8140679
[TBL] [Abstract][Full Text] [Related]
19. Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Seishima M; Satoh S; Nojiri M; Osada K; Kitajima Y
J Invest Dermatol; 1997 Nov; 109(5):650-5. PubMed ID: 9347794
[TBL] [Abstract][Full Text] [Related]
20. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Kirchheimer JC; Wojta J; Christ G; Binder BR
Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5424-8. PubMed ID: 2501786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
